Nadolol - Invion

Drug Profile

Nadolol - Invion

Alternative Names: INV 102; INV102 controlled release; INV102 CR

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inverseon
  • Developer Invion
  • Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta adrenergic receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Asthma; Chronic obstructive pulmonary disease

Highest Development Phases

  • Phase II Asthma; Smoking withdrawal
  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 26 Sep 2017 Nadolol is still at phase II development stage for Asthma and Smoking withdrawal in USA (PO) (Invion Annual report, June 2017)
  • 30 Jun 2017 Nadolol from Invion is available for licensing as of 26 Sep 2017. http://inviongroup.com/investors/
  • 07 Jul 2016 Invion plans a phase III trial for Smoking withdrawal (in patients with Chronic obstructive pulmonary disease) in USA (PO) (Invion investor newsletter, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top